핵의학 시장 예측(-2030년) : 부문별, 지역별 세계 분석

According to Stratistics MRC, the Global Nuclear Medicine Market is accounted for $10.3 billion in 2023 and is expected to reach $25.5 billion by 2030 growing at a CAGR of 13.8% during the forecast period. Nuclear medicine is a specialty that examines the structure, and occasionally the operation, of an organ in the human body using a very small amount of radiology or other radioactive elements. It is mostly utilized for various disorders that require nuclear medicine for diagnosis and treatment. Radiopharmaceuticals are utilized during the course of the treatment. This kind of treatment is required for a variety of conditions, including hyperthyroidism, various forms of bone pain, and thyroid cancer.

According to American Heart Association 2022, approximately 19.1 million deaths were attributed to CVD globally in 2020. The age-adjusted death rate per 100,000 population was 239.8 and age-adjusted prevalence rate was 7354.1 per 100,000.

Market Dynamics:

Driver:

Rise in prevalence of cancer and cardiac disorders

This rise in disease burden necessitates advanced diagnostic and treatment options, where nuclear medicine plays a pivotal role. The technique's ability to offer accurate and early disease detection, precise treatment monitoring, and targeted therapies has garnered attention from both healthcare providers and patients. As a result, the increasing demand for efficient and personalized healthcare solutions in the face of these mounting health challenges has spurred the expansion of the nuclear medicine sector, driving innovation and market advancement.

Restraint:

High cost of the diagnostic and therapeutic equipment and procedures

The intricate technologies and specialized materials required for nuclear imaging and treatments contribute to elevated upfront expenses. Moreover, the need for skilled personnel, maintenance, and regulatory compliance further amplifies the financial burden. These high costs can impede accessibility to nuclear medicine services, limiting adoption rates, particularly in resource-constrained healthcare systems. Addressing the affordability challenge becomes pivotal to ensuring wider utilization of nuclear medicine, as reducing costs without compromising quality remains a critical factor for market expansion and equitable healthcare delivery.

Opportunity:

Increasing demand for image guided procedures and diagnostics

Many major companies and SMEs are implementing Nuclear Medicine because they improve production processes. Production efficiency is aided by these systems' capacity to boost output, cut costs, boost quality, enabling real-time data collecting and monitoring of products. This aspect is anticipated to promote the use of these systems in order to boost revenues. The use of Nuclear Medicine also results in decreases in the amount of waste and energy used throughout the production process. For instance, putting a MES solution on a shop floor eliminates the need for paperwork and physical storage space while not requiring extra IT resources.

Threat:

Stringent regulatory guidelines

As the industry evolves, adherence to complex and evolving regulations becomes paramount. These guidelines encompass safety, efficacy, and ethical considerations, often requiring rigorous testing and approval processes for new technologies and radiopharmaceuticals. The time and resources needed for compliance can hinder innovation, delay product launches, and increase development costs. Struggling to meet these requirements might deter new entrants and limit market growth. Consequently, navigating the intricate landscape of regulatory constraints emerges as a substantial challenge, potentially impeding the swift advancement of nuclear medicine solutions.

COVID-19 Impact:

The COVID-19 pandemic had a significant impact on the nuclear medicine market. Elective procedures and routine imaging faced delays due to resource reallocation and safety concerns, leading to decreased patient volumes. Supply chain disruptions affected the availability of radiopharmaceuticals and equipment, causing fluctuations in the market. However, the crisis underscored the value of nuclear medicine for rapid disease diagnosis and treatment monitoring. Telemedicine and remote reporting gained traction, reshaping service delivery.

The positron emission tomography (pet) applications segment is expected to be the largest during the forecast period

The positron emission tomography (pet) applications segment is expected to have a lucrative growth. It enables precise visualization and quantification of metabolic and functional processes within the body. PET is crucial for oncology, aiding in early cancer detection, accurate staging, and monitoring treatment response. Neurology benefits from PET scans for diagnosing brain disorders like Alzheimer's and epilepsy. Cardiovascular diseases are assessed through PET's ability to evaluate blood flow and heart function. Moreover, PET facilitates the development of novel radiopharmaceuticals and supports research in drug discovery. Its non-invasive nature and quantitative data make PET a cornerstone for advancing personalized and targeted medical interventions.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is anticipated to witness the fastest CAGR growth during the forecast period. Hospitals in the nuclear medicine market serve as primary hubs for diagnosis, treatment, and research. Equipped with advanced imaging equipment like PET, SPECT, and gamma cameras, hospitals provide essential nuclear medicine services. They cater to a wide range of patients, offering precise disease detection, accurate staging, and therapy monitoring. Nuclear medicine departments within hospitals collaborate with multidisciplinary teams to enhance patient care, often integrating imaging with other medical specialties. Furthermore, hospitals contribute significantly to the development and evaluation of innovative radiopharmaceuticals and imaging techniques, fostering continuous advancements in nuclear medicine for improved patient outcomes.

Region with largest share:

During the forecast period, it is expected that the North American Nuclear Medicine market will continue to hold a majority of the market share due to its advanced healthcare infrastructure and research capabilities. The region's well-established medical facilities and academic institutions drive innovation in imaging technologies and radiopharmaceutical development. The high prevalence of chronic diseases, including cancer and cardiovascular disorders, fuels the demand for nuclear medicine services. North America's robust regulatory framework ensures safety and quality standards. The presence of key market players, collaborations with research organizations, and increasing investments in healthcare contribute to the region's leadership in nuclear medicine, making it a hub for cutting-edge diagnostic and therapeutic applications.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, due to its increasing healthcare investments, rising awareness of early disease detection, and a growing geriatric population drive the demand for advanced diagnostic and therapeutic solutions. The region's expanding healthcare infrastructure, coupled with improving economic conditions, fosters the adoption of nuclear medicine technologies. Moreover, Asia Pacific's diverse patient pool provides ample opportunities for clinical research and trials, contributing to the development of innovative radiopharmaceuticals and imaging techniques. With a blend of emerging markets and technological advancements, Asia Pacific is poised to play a significant role in shaping the future of nuclear medicine.

Key players in the market:

Some of the key players in Nuclear Medicine market include: Isotopia Molecular Imaging Ltd., Jubilant Draximage, Inc., Lantheus Holdings, Inc., Cardinal Health, Global Medical Solutions, Pharmalogic Holdings Corp., Shine Technologies, llc, Ire Elit, Eczacibasi-Monrol Nuclear Products, GE Healthcare, Bayer AG, Bracco Imaging S.P.A., Nordion Inc., Northstar Medical Radioisotopes, Isotope JSC, Siemens Healthineers, Yantai Dongcheng Pharmaceutical Group Co., Ltd. and Eckert & Ziegler.

Key Developments:

In March 2023, Life Healthcare acquired TheraMed Nuclear's non-clinical imaging operations in Gauteng with an aim to expand its geographical presence in South Africa.

In February 2023, Telix Pharmaceuticals Limited announced the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) in February 2021. This project aims to create and validate a generator-based theranostic compound for urologic oncology targeting PSMA and utilising the beta-emitting isotope rhenium-188 (188Re).

In January 2023, Nuclear medicines are a group of pharmaceutical drugs that contain radioactive isotopes. They are exclusive medicinal formulations with radioisotopes and are used in major clinical areas for diagnosis or therapy.

In November 2022, Curium announced that the US Food and Drug Administration (FDA) approved DaTscan (Ioflupane I 123 Injection) to assist in evaluating adult patients with suspected Parkinsonian Syndromes.

Types Covered:

• Diagnostic Nuclear Medicine
• Therapeutic Nuclear Medicine
• Brachytherapy Isotopes
• Other Types

Applications Covered:

• Diagnostic Applications
• Other Applications

End Users Covered:

• Hospitals
• Imaging Centers
• Academic & Research Centers
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Nuclear Medicine Market, By Type

• 5.1 Introduction
• 5.2 Diagnostic Nuclear Medicine
  • 5.2.1 Single Photon Emission Computerized Tomography (SPECT) Radiopharmaceuticals
    • 5.2.1.1 Technetium-99m
    • 5.2.1.2 Iodine-123
    • 5.2.1.3 Thallium-201
    • 5.2.1.4 Gallium-67
  • 5.2.2 Positron Emission Tomography (PET) Radiopharmaceuticals
    • 5.2.2.1 Fluorine-18
    • 5.2.2.2 Rubidium-82
• 5.3 Therapeutic Nuclear Medicine
  • 5.3.1 Alpha Emitters
    • 5.3.1.1 Radium-223
  • 5.3.2 Beta Emitters
    • 5.3.2.1 Iodine-131
    • 5.3.2.2 Yittrium-90
    • 5.3.2.3 Samarium-153
    • 5.3.2.4 Lutetium-177
    • 5.3.2.5 Rhenium-186
• 5.4 Brachytherapy Isotopes
  • 5.4.1 Iodine-125
  • 5.4.2 Iridium-192
  • 5.4.3 Palladium-103
  • 5.4.4 Cesium-131
• 5.5 Other Types

6 Global Nuclear Medicine Market, By Application

• 6.1 Introduction
• 6.2 Diagnostic Applications
  • 6.2.1 Single Photon Emission Computerized Tomography (SPECT) Applications
    • 6.2.1.2 Cardiology
    • 6.2.1.3 Bone Scans
    • 6.2.1.4 Thyroid Applications
    • 6.2.1.5 Pulmonary Scans
  • 6.2.2 Positron Emission Tomography (PET) Applications
    • 6.2.2.1 Oncology
    • 6.2.2.2 Cardiology
    • 6.2.2.3 Neurology
  • 6.2.3 Therapeutic Applications
    • 6.2.3.1 Thyroid Indications
    • 6.2.3.2 Bone Metastasis
    • 6.2.3.3 Lymphoma
    • 6.2.3.4 Endocrine Tumors
• 6.3 Other Applications

7 Global Nuclear Medicine Market, By End User

• 7.1 Introduction
• 7.2 Hospitals
• 7.3 Imaging Centers
• 7.4 Academic & Research Centers
• 7.5 Other End Users

8 Global Nuclear Medicine Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Isotopia Molecular Imaging Ltd.
• 10.2 Jubilant Draximage, Inc.
• 10.3 Lantheus Holdings, Inc.
• 10.4 Cardinal Health
• 10.5 Global Medical Solutions
• 10.6 Pharmalogic Holdings Corp.
• 10.7 Shine Technologies, llc
• 10.8 Ire Elit
• 10.9 Eczacibasi-Monrol Nuclear Products
• 10.10 GE Healthcare
• 10.11 Bayer AG
• 10.12 Bracco Imaging S.P.A.
• 10.13 Nordion Inc.
• 10.14 Northstar Medical Radioisotopes
• 10.15 Isotope JSC
• 10.16 Siemens Healthineers
• 10.17 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
• 10.18 Eckert & Ziegler